Trials / Completed
CompletedNCT03117270
A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Efficacy and Safety of Filgotinib Administered for 12 Weeks to Subjects With Active Ankylosing Spondylitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, Phase 2, double-blind, placebo-controlled study in subjects with active Ankylosing Spondylitis (AS). A total of approximately 100 subjects will be randomized to one of 2 treatment arms in a 1:1 ratio: oral filgotinib tablets q.d. or matching placebo q.d. Treatment duration will be 12 weeks. Each subject will stay in the study for a maximum of 20 weeks (from Screening visit to Follow-up visit).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | filgotinib | one filgotinib oral tablet q.d. |
| DRUG | Placebo Oral Tablet | one placebo oral tablet q.d. |
Timeline
- Start date
- 2017-03-07
- Primary completion
- 2018-07-02
- Completion
- 2018-07-02
- First posted
- 2017-04-17
- Last updated
- 2018-08-13
Locations
30 sites across 7 countries: Belgium, Bulgaria, Czechia, Estonia, Poland, Spain, Ukraine
Source: ClinicalTrials.gov record NCT03117270. Inclusion in this directory is not an endorsement.